Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients

International Journal of Biological Markers

Volumn 24, Issue 3, 2009, Pages 142-146

  Saglam, Sezer ^a   Suzme, Rafi ^b   Gurdol, Figen ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; ERBB2; Her2 neu; Interleukin 2; Tumor necrosis factor alpha

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; NUCLEIC ACID AMPLIFICATION; PRIMARY TUMOR; PROTEIN BLOOD LEVEL;

EID: 70449427454     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4663     Document Type: Article

References (32)

1. Crowe JP, Patrick RJ, Rybicki LA, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast 2006; 15: 728-35.
2. Ross JS, Fletcher JA. The Her-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3: 237-52.
3. Witzel I, Thomssen C, Krenkel S, et al. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers 2006; 21: 131-40.
4. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004; 19: 14-22.
5. Luftner D, Henschke P, Kafka A, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer: a question of standardization, automation and timing. Int J Biol Markers 2004; 19: 1-13.
6. Müller V, Thomssen C, Karakas C, et al. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 2003; 18: 13-20.
7. Tang P, Hung MC, Klostergaard J. TNF cytotoxicity: effects of HER-2/neu expression and inhibitors of ADP-ribosylation. Lymphokine Cytokine Res 1994; 13: 117-23.
8. Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9: R15.
9. Lyon DE, McCain NL, Walter J, Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 2008; 57: 51-8.
10. Weitsman, GE, Ravid A, Lieberman UA, Koren R. Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann N Y Acad Sci 2003; 1010: 437-40.
11. Lyu MA, Rosenblum MG. The immunocytokine scFv23/TNF sensitizes HER-2/ neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther 2005; 8: 1205-13.
12. Zielinski CC, Budinsky AC, Wagner TM, et al. Defect of tumor necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat 2003; 81: 99-105.
13. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43: 211-5.
14. Melczer Z, Banhidy F, Csomor S, Siklos P, Dworak O, Cseh K. ErbB-2/HER-2 protein expression, serum tumour necrosis factor-alpha (TNF-alpha) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2003, 24: 138-142.
15. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res 2004; 6: R1-7.
16. Azzarone B, Pottin-Clemenceau C, Krief P. Are interleukin-2 and interleukin-15 tumor promoting factors for human nonhematopoietic cells? Eur Cytokine Netw 1996; 7: 27-36.
17. Saks S, Rosenblum M. Recombinant human TNF-α: preclinical studies and results from early clinical trial. Immunol Ser 1992, 56, 567-87.
18. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000; 20: 4087-96.
19. Hoffmann M, Schmidt M, Wels W. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-α. Cancer Immunol Immunother 1998; 47: 167-75.
20. Sleijfer S, Asschert JGW, Timmer-Bosscha H, Mulder NH. Enhanced sensitivity to tumor necrosis factor-α in doxorubicin-resistant tumor cell lines due to downregulated c-erbB2. Int J Cancer 1998; 77: 101-6.
21. Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res 1990; 50: 7364-70.
22. Lichtenstein A, Fady C, Gera JF, et al. Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. Cell Immunol 1992; 141: 219-32.
23. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000; 275: 8027-31.
24. Wang X, Li N, Li H, et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-α-induced apoptosis and cell growth arrest. Clin Cancer Res 2005; 11: 7545-53.
25. Szlosarek, PW, Balkwill, FR. Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 2003; 4: 565-73.
26. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A 1991; 88: 9292-6.
27. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Role of tumor necrosis factor-α and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 2006; 97: 1044-9.
28. Nunes RA, Li X, Kang SP, et al. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers 2009; 24: 1-10.
29. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004; 25: 94-102.
30. Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine response to class II HER-2/neu- associated peptides in breast cancer patients. Clin Cancer Res 1998; 4: 2015-24.
31. Laouar Y, Crispe IN. Functional flexibility in T cells: independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity 2000; 13: 291-301.
32. Lea NC, Orr SJ, Stoeber K, et al. Commitment point during G0-G1 that controls entry into the cell cycle. Mol Cell Biol 2003; 23: 2351-61.